141 related articles for article (PubMed ID: 26436696)
1. A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.
Zdobnova T; Sokolova E; Stremovskiy O; Karpenko D; Telford W; Turchin I; Balalaeva I; Deyev S
Oncotarget; 2015 Oct; 6(31):30919-28. PubMed ID: 26436696
[TBL] [Abstract][Full Text] [Related]
2. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
[TBL] [Abstract][Full Text] [Related]
3. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
4. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
6. Far-red fluorescent cell line for preclinical study of HER2-targeted agents.
Balalaeva IV; Sokolova EA; Brilkina AA; Deyev SM; Petrov RV
Dokl Biochem Biophys; 2015; 465():410-2. PubMed ID: 26728737
[TBL] [Abstract][Full Text] [Related]
7. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.
Sokolova EA; Shilova ON; Kiseleva DV; Schulga AA; Balalaeva IV; Deyev SM
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096563
[TBL] [Abstract][Full Text] [Related]
8. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
[TBL] [Abstract][Full Text] [Related]
9. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
13. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
14. Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.
Mironova KE; Proshkina GM; Ryabova AV; Stremovskiy OA; Lukyanov SA; Petrov RV; Deyev SM
Theranostics; 2013; 3(11):831-40. PubMed ID: 24312153
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
Zhang DX; Zhao PT; Xia L; Liu LL; Liang J; Zhai HH; Zhang HB; Guo XG; Wu KC; Xu YM; Jia LT; Yang AG; Chen SY; Fan DM
Gut; 2010 Mar; 59(3):292-9. PubMed ID: 19951902
[TBL] [Abstract][Full Text] [Related]
17. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
[TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
19. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
20. Development and investigation of recombinant immunotoxin protein 4D5scFv-mCherry-PE(40).
Shilova ON; Souslova EA; Pilunov AM; Deyev SM; Petrov RV
Dokl Biochem Biophys; 2016 Nov; 471(1):450-453. PubMed ID: 28058684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
